These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16456812)

  • 1. Critical analysis of prostate-specific antigen doubling time calculation methodology.
    Svatek RS; Shulman M; Choudhary PK; Benaim E
    Cancer; 2006 Mar; 106(5):1047-53. PubMed ID: 16456812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.
    Valicenti RK; DeSilvio M; Hanks GE; Porter A; Brereton H; Rosenthal SA; Shipley WU; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1064-71. PubMed ID: 16979837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
    Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using splines to detect changes in PSA doubling times.
    Guess B; Jennrich R; Johnson H; Redheffer R; Scholz M
    Prostate; 2003 Feb; 54(2):88-94. PubMed ID: 12497581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
    Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
    Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
    Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
    Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models.
    Symon Z; Kundel Y; Sadetzki S; Oberman B; Ramon J; Laufer M; Catane R; Pfeffer MR
    Am J Clin Oncol; 2006 Oct; 29(5):446-50. PubMed ID: 17023777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
    Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
    J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
    Sandblom G; Ladjevardi S; Garmo H; Varenhorst E
    Cancer; 2008 Feb; 112(4):813-9. PubMed ID: 18098207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Ann Epidemiol; 2008 Apr; 18(4):270-82. PubMed ID: 18374279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
    Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
    Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current applications for prostate-specific antigen doubling time.
    Ramírez ML; Nelson EC; Devere White RW; Lara PN; Evans CP
    Eur Urol; 2008 Aug; 54(2):291-300. PubMed ID: 18439749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.